UNSPSC 51434959: Indapamide/Perindopril arginine

It is an antihypertensive and is used in the treatment of high blood pressure (hypertension).

UNSPSC 51434959 Indapamide/Perindopril arginine is a Commodity code with minimal recent state and local procurement activity directly aligned with pharmaceutical product sourcing. The recent opportunities tagged with this code show a significant mismatch between the code's nominal scope—a specific combination antihypertensive medication—and what state and local jurisdictions are actually buying. Of the fourteen opportunities in the dataset, most are either unrelated network events (Clay County Procurement Conference, Marion County Reverse Trade Show), facility operational requests (Palm Bay Aquatic Center), or broad pharmaceutical and medical supply services that do not target this specific drug formulation. Two opportunities—Dane County's RFP for comprehensive pharmaceutical services to Badger Prairie Health Care Center and West Texas Centers' request for prescription and pharmacy services across 35 sites—involve pharmacy operations and medication distribution but do not specify this combination product. A Collier County notice of intent to single-source Handtevy, a drug-dosage calculation application, and Seminole County's procurement of naloxone and drug deactivation systems are similarly tangential. The City of Tucson's RFP for BLS/ALS pharmaceuticals and supplies and Pinellas County's procurement of certified drug reference standards for forensic analysis do not reference this specific medication combination. One District of Columbia pharmacy benefits program network qualification request and a Washington County, Oregon naloxone distribution center letter of interest provide insufficient scope detail.

Geographic spread across the recent sample includes Florida (Collier, Dane, Seminole, Marion, Pinellas counties and Palm Bay), Texas (Tucson, West Texas Centers), Wisconsin (Dane County), Oregon (Washington County), and the District of Columbia, reflecting fragmented rather than concentrated demand. No representative recent opportunities directly soliciting Indapamide/Perindopril arginine or similar proprietary combination medications have been posted. The code shows little relevant procurement activity and may be misapplied in the dataset; business development professionals should verify whether state and local health systems, managed-care entities, or pharmacy benefit managers are actually sourcing this specific formulation through formal competitive processes, as the recent record does not support active pursuit under this code classification.